Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries.
The investigators tested whether abciximab-coated stents prevent neointimal hyperplasia (NIH) formation in coronary de novo lesions. Abciximab-coated stents were compared with control stents. All patients underwent follow-up coronary angiography and intravascular ultrasound (IVUS). All stents were successfully deployed, and patients were discharged home without clinical events. At follow-up coronary angiography, the restenosis rate and late loss were 14% and 0.33 +/- 0.28 mm in the abciximab-coated stent group and 28.6% and 0.64 +/- 0.32 mm in the control stent group (p = 0.099 and p = 0.014, respectively). At follow-up IVUS, the intrastent luminal area and intrastent NIH area were 5.7 +/- 1.6 and 2.0 +/- 1.6 mm(2), respectively, in the abciximab-coated stent group and 4.2 +/- 0.8 and 3.4 +/- 1.7 mm(2), respectively, in the control stent group (p = 0.001 and p = 0.001, respectively). Abciximab-coated stents are feasible and significantly inhibit NIH, with potential therapeutic benefit in preventing stent restenosis.
Hong
Young Joon
YJ
The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Science, Gwangju, Korea.
Jeong
Myung Ho
MH
Kim
Weon
W
Lim
Sang Yup
SY
Lee
Sang Hyun
SH
Hong
Seo Na
SN
Kim
Ju Han
JH
Ahn
Young Keun
YK
Cho
Jeong Gwan
JG
Park
Jong Chun
JC
Cho
Dong Lyun
DL
Kim
Hoon
H
Kang
Jung Chaee
JC
D000077284:Abciximab; D000208:Acute Disease; D000789:Angina, Unstable / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000925:Anticoagulants / Q000008:administration & dosage*; D003331:Coronary Vessels / Q000473:pathology*; D004337:Drug Carriers; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006965:Hyperplasia / Q000517:prevention & control; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D011446:Prospective Studies; D015607:Stents; D013577:Syndrome; D017539:Tunica Intima / Q000473:pathology*
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D004337:Drug Carriers; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab